Related Experiment Video

Updated: Jun 5, 2026

Stereotactic Adoptive Transfer of Cytotoxic Immune Cells in Murine Models of Orthotopic Human Glioblastoma Multiforme Xenografts
11:15

Stereotactic Adoptive Transfer of Cytotoxic Immune Cells in Murine Models of Orthotopic Human Glioblastoma Multiforme Xenografts

Published on: September 1, 2018

Molecular alterations in glioblastoma: potential targets for immunotherapy

Azizul Haque1, Naren L Banik, Swapan K Ray

  • 1Department of Microbiology and Immunology, Medical University of South Carolina, Charleston, South Carolina, USA.

Progress in Molecular Biology and Translational Science
|January 5, 2011
PubMed

Insights

Glioblastoma, a deadly brain tumor, involves genetic changes affecting antigen expression. Understanding these alterations and immune responses is key to developing new chemoimmunotherapies for better patient outcomes.

Area of Science:

  • Neuro-oncology
  • Cancer immunology
  • Molecular oncology

Background:

  • Glioblastoma is the most aggressive primary brain tumor with poor patient prognosis.
  • Current treatments like surgery, radiation, and chemotherapy offer limited efficacy.
  • Genetic and epigenetic alterations drive glioblastoma development and influence therapeutic targets.

Purpose of the Study:

  • To review genetic alterations in glioblastoma.
  • To examine the impact of these alterations on antigen and biomarker expression.
  • To explore the potential for novel chemoimmunotherapeutic strategies.

Main Methods:

  • Literature review focusing on genetic alterations in glioblastoma.
  • Analysis of antigen and biomarker expression in relation to genetic changes.
  • Discussion of glioblastoma-specific immune responses and the tumor microenvironment.

Main Results:

  • Glioblastoma exhibits numerous cytogenetic, chromosomal, and genetic alterations.
  • These alterations lead to distinct antigen and biomarker expression profiles.
  • Limited knowledge exists regarding glioblastoma-specific immune responses.

Conclusions:

  • Understanding molecular interactions within the glioblastoma tumor microenvironment is crucial.
  • Targeting genetic alterations and immune escape pathways can inform novel therapeutic designs.
  • Integrated chemoimmunotherapy approaches hold promise for improved glioblastoma treatment.

More Related Videos

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care12:55

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Published on: February 16, 2015

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...